Merck & Co., Inc. (6MK.F)
| Previous close | 121.20 |
| Open | 120.40 |
| Bid | 120.20 x 100000 |
| Ask | 120.40 x 100000 |
| Day's range | 120.20 - 120.60 |
| 52-week range | 90.70 - 123.20 |
| Volume | |
| Avg. volume | 342 |
| Market cap | 305.756B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.82 |
| EPS (TTM) | 0.83 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 2.84 (2.36%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
Simply Wall St.Insiders At Merck Sold US$12m In Stock, Alluding To Potential Weakness
The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...
Zacks5 Stocks Powering the Dow ETF Year to Date
The Dow Jones touched the milestone of 40,000 for the first time on strong corporate earnings and renewed bets for rate cuts. We have highlighted five ETFs that have been leading the way higher this year.
BenzingaPfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
